Table 1.
A summary of all measured variables collected from serum, urine, and MSOT in the present study.
| Non-DM control | DM | DM ± DSS | ||
|---|---|---|---|---|
| Baseline measurement | ||||
| Obesity | Body weight (g) | 20.8 ± 0.69 | 51.79 ± 4.03∗ | 50.21 ± 3.08∗ |
| Serum | Fasting glucose (mmol/l) | 7.58 ± 0.60 | 23.83 ± 5.10∗ | 19.60 ± 3.58∗ |
| After 3 weeks | ||||
| Obesity | Body weight (g) | 18.78 ± 1.21 | 56.52 ± 6.07∗ | 57.09 ± 4.03∗ |
| Serum | Fasting glucose (mmol/l) | 8.17 ± 1.36 | 24.24 ± 6.67∗ | 24.97 ± 6.32∗ |
| Creatinine (μmol/l) | 9.79 ± 1.37 | 14.90 ± 3.79∗ | 14.80 ± 3.10∗ | |
| Total bilirubin (μmol/l) | 1.40 ± 0.21 | 1.50 ± 0.51 | 1.69 ± 0.32 | |
| Conjugated bilirubin (μmol/l) | 0.35 ± 0.10 | 0.43 ± 0.11 | 0.41 ± 0.16 | |
| Unconjugated bilirubin (μmol/l) | 1.02 ± 0.23 | 1.10 ± 0.58 | 1.33 ± 0.37 | |
| Urine | F2-isoprostane (ng/mg of creatinine) | 15.82 ± 8.73# | 24.46 ± 6.59 | 18.00 ± 6.39 |
| Urinary albumin : creatinine ratio (mg/g of creatinine) | 33.5 ± 14.86 | 115.7 ± 41.54∗ | 118.2 ± 47.31∗ | |
| MSOT | Tmax delay (s) | 90.21 ± 14.93 | 142.97 ± 13.96∗ | 81.96 ± 19.51 |
All data presented as mean ± SD. ∗ denotes p < 0.05 when this group is compared to the non-DM control group. # denotes p < 0.05 when this group is compared to the DM group.